GlassScriptPhysician profile
Toni Usev
NPI 1720420714
$6,407.13
in general payments reported to CMS, 2019-2025
13 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,115 · 2022: $995 · 2023: $998 · 2024: $1,330 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,927.74 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $934.19 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $915.88 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $578.72 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $553.98 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $353.74 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $339.33 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $243.17 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $230.76 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $153.99 | 2021-2024 | Invega |
| Corium, LLC | $117.08 | 2022-2025 | Azstarys |
| Luye Pharma (USA) LTD. | $29.50 | 2025 | Erzofri Extended-Release |
| Braeburn INC. | $29.05 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Usev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.